ライフサイエンスコーパス: HIV-negative

1 uded after group assignment owing to testing HIV negative.

2 n clinical trials alongside patients who are HIV negative.

3 (aged 3 years or older and immunocompetent [HIV-negative]).

4 Of these individuals, 69 121 tested HIV-negative, 12 935 of whom had elevated HIV risk (1353

5 ificantly higher in MSM than MSW, both among HIV-negative (14% vs 3%; prevalence ratio (PR) 4.7; 95%

6 isk of HIV (25%), knowledge that partner was HIV negative (24%), experiencing side effects (20%), and

7 ) were reported in 96 MSM (HIV-infected, 72; HIV-negative, 24).

8 te Type IV-B, was the most prevalent in both HIV-negative (38% at baseline, 30% at the follow-up visi

9 ase of KS in a human immunodeficiency virus (HIV)-negative 47-year old male with UC after treatment w

10 ly tested for syphilis annually increased in HIV-negative (48% to 91%; Ptrend < .0001) and HIV-positi

11 n People Living with HIV (PLHIV) compared to HIV-negative (62% versus 51%), driven by their higher ag

12 den is projected to increase by 2035 (56% in HIV-negative; 71% in PLHIV), with population growth doub

13 r HIV status (HIV-positive 94%, unknown 35%, HIV-negative 8%; p < 0.001) and marital status (28% unma

14 (PR) of comorbidities in HIV-positive versus HIV-negative admissions over time.

15 rbidity disparities between HIV-positive and HIV-negative admissions were mild liver disease (PR=4.9,

16 To investigate this, 130 HIV negative adolescent females aged 15-19 years were en

17 , double-blinded dose-escalation study in an HIV-negative adult South African cohort (n = 72) with ac

18 f 657 eligible human immunodeficiency virus (HIV)-negative adults from a TB household contact study w

19 ed with EDTA plasma (n = 1,301) and DBS from HIV-negative adults (n = 1,000).

20 higher among HIV-infected adults relative to HIV-negative adults (P = .0002, P = .04, and P = .0017,

21 HIV-infected adults relative to age-matched HIV-negative adults (P = .01, P = .01, and P = .02, resp

22 f such therapy with dolutegravir in healthy, HIV-negative adults was halted early after two of the fo

23 oup, multicentre phase 2 trial, we recruited HIV-negative adults with de novo or transformed DLBCL an

24 contributing to prevention services for the HIV-negative adults.

25 2304 PWIDs were recruited, 1200 of whom were HIV negative and are included in the present study.

26 transgender women aged 18-70 years who were HIV negative and had participated in three previous PrEP

27 hom initiated ART within 28 days; 222 tested HIV negative and were not already circumcised, of whom 1

28 %-12.3%) among human immunodeficiency virus (HIV)-negative and HIV-positive persons, respectively.

29 121 women aged 30-65 years, 586 of whom were HIV-negative and 535 HIV-positive.

30 analyse differences in HRQoL scores between HIV-negative and HIV-positive individuals who were unawa

31 799 and 1032 syphilis cases were detected in HIV-negative and HIV-positive MSM, respectively.

32 been used to compare the oral microbiota of HIV-negative and HIV-positive persons, both with and wit

33 Hb) in capillary and venous blood samples of HIV-negative and HIV-positive subjects.

34 We recruited HIV-negative and HIV-positive women aged 30-65 years fro

35 microbiota and persistent hrHPV infection in HIV-negative and HIV-positive women.

36 n (67%, 142/211 HIV-positive and 33%, 69/211 HIV-negative) and evaluated the association between the

37 ancies: 3,339 were HIV-positive, 10,958 were HIV-negative, and 15,994 had unknown HIV status at deliv

38 y 6 months provided by participants who were HIV negative at baseline to estimate the primary outcome

39 med consent, and, for this paper, who tested HIV negative at baseline were recruited from the streets

40 aternal and child health services who tested HIV negative at that visit or within a month and were wi

41 3222 participants who were HIV-negative at baseline, and who had at least one repea

42 donated by 22 mothers (15 HIV-infected and 7 HIV-negative) at 4-16 weeks postpartum, then analyzed by

43 of the BTS, non-pregnant, non-breastfeeding, HIV-negative BTS participants, all of whom were current

44 Compared to human immunodeficiency virus (HIV)-negative cases, HIV type 1-coinfected cases had mor

45 nes was performed on select HIV-positive and HIV-negative cases in PD-L1+ tumor areas associated with

46 Among 119 HIV-negative cases with confirmed bacterial pneumonia, 7

47 city (PWV) were evaluated in 101 PHIV and 96 HIV negative children (HIV-).

48 Data from 1802 human immunodeficiency virus (HIV)-negative children aged 1-59 months enrolled in the

49 children had increased mortality compared to HIV-negative children (aHR, 6.85; 95% CI, 4.60-10.19) an

50 ohort study, collected data over 3 visits on HIV-negative children ages 7 to 11 years in rural South

51 In both high- and low-income countries, HIV-negative children born to HIV-positive mothers (HIV

52 combining the VTS sample with 629 same-aged HIV-negative children from the local demographic platfor

53 mpare TL in HIV+ (cART-naive or treated) and HIV-negative children with and without CLD.

54 This HIV-negative cohort allowed us to assess cellular immune

55 and chest radiography was rare in our mostly HIV-negative cohort.

56 235 (62%) of 380 sexual partners who tested HIV-negative, compared with eight (18%) of 45 who tested

57 rural areas of Uganda who self-identified as HIV negative completed interviews that included measures

58 itively normal human immunodeficiency virus (HIV)-negative control individuals, 20 HIV-negative patie

59 sample of persons with HIV under HAART to an HIV-negative control group showed a complex set of clini

60 ere similar for HIV-positive individuals and HIV-negative control individuals.

61 city- and socioeconomic status (SES)-matched HIV-negative controls (HIV-).

62 nd cART-naive, or on cART for >6 months, and HIV-negative controls of similar age and sex.

63 CD16(+) NK cells are more abundant in EC and HIV-negative controls than in VNC and that the frequency

64 receiving suppressive cART and 79 comparable HIV-negative controls, aged >/=45 years, from the Comorb

65 i-site prospective cohort study of WLHIV and HIV-negative controls.

66 oung adults with lifelong HIV and 20 matched HIV-negative controls.

67 reated HIV-infected patients were matched to HIV-negative controls.

68 -infected patients compared with appropriate HIV-negative controls.

69 ve women naive to antiretroviral therapy and HIV-negative controls.

70 ter overall life expectancies than did their HIV-negative counterparts in the general population [29.

71 n HIV-infected women, in comparison to their HIV-negative counterparts.

72 cted patients are higher than those in their HIV-negative counterparts.

73 HIV-infected individuals compared with their HIV-negative counterparts.

74 Genital HPV was assessed in 725 concordant HIV-negative couples and 209 HIV-positive couples enroll

75 pes were detected in both partners in 60% of HIV-negative couples and 96% of HIV-positive couples ove

76 For HIV-negative couples, genotypic concordance was 30% at b

77 althy (of 36 consecutive eligible patients), HIV-negative cryptococcal meningoencephalitis (CM) patie

78 lticenter pilot study comparing HIV D+/R+ vs HIV-negative donor to HIV+ recipient (HIV D-/R+) kidney

79 age among children born to mothers who were HIV negative during pregnancy.

80 ) PrEP as part of combination prevention for HIV-negative FSWs and (2) early ART for HIV-positive FSW

81 We enrolled HIV-negative gay and other men who have sex with men who

82 on in HIV-positive persons under HAART to an HIV-negative group using 16S rRNA gene sequence analysis

83 ortality was similar in the HIV-positive vs. HIV-negative groups (26.7% vs. 32.1%; p=0.16), but in th

84 in rectal and nasal fluids of both HIV+ and HIV-negative HCV patients with high serum HCV-RNA, indep

85 ource Consortium and 67 seminal samples from HIV-negative healthy controls.

86 se patients as human immunodeficiency virus (HIV)-negative HHCs with blood samples in whom tuberculos

87 Among 6751 HIV-negative HHCs with baseline blood samples, 192 had s

88 een ARV use and adverse birth outcomes among HIV-negative HIV-exposed infants.

89 encephalitis in both HIV positive (HIV+) and HIV negative (HIV-) subjects is associated with high mor

90 (-) CD4 T cells from the blood and rectum of HIV-negative (HIV(-)) and antiretroviral therapy (ART)-s

91 n immunodeficiency virus (HIV) compared with HIV-negative (HIV-) adolescents.

92 the numbers of circulating CD4+ cells in the HIV-negative (HIV-) brain-dead donor (BDD) is not known.

93 city (PWV) were evaluated in 101 PHIV and 96 HIV-negative (HIV-) children.

94 areas of dysplasia and 22 patients who were HIV-negative (HIV-) with AGWs seen between February 2013

95 incident TB in a prospective cohort of 6,751 HIV-negative household contacts of TB patients enrolled

96 validated in an independent cohort of 1,948 HIV-negative household TB contacts from The Gambia (aged

97 veillance (NHBS) system among MSM who tested HIV negative in NHBS and were currently sexually active.

98 of people known to be HIV-positive or tested HIV-negative in the preceding 12 months; proportion of p

99 ileum of 19 INR and 20 IR in addition to 20 HIV negative individuals.

100 Consecutive PLWH (n = 169) and at-risk HIV-negative individuals (n = 126) were recruited from 2

101 g was associated with dolichoectasia only in HIV-negative individuals (P = <.001).

102 prevalence in HIV-infected individuals than HIV-negative individuals across all risk groups and regi

103 lerosis was observed in HIV-positive than in HIV-negative individuals across the age groups 18-29 yea

104 Plasma and blood CD4+ T cells isolated from HIV-negative individuals across the Mtb infection spectr

105 HIV-positive and HIV-negative individuals aged 18 years and older were re

106 fidence interval [CI], -2.8 to .1) less than HIV-negative individuals during the first 2 months of tu

107 ve and 784 of 2850 (27.5%, 95% CI 25.9-29.2) HIV-negative individuals had subclinical atherosclerosis

108 equalities in HRQoL between HIV-positive and HIV-negative individuals in this general population samp

109 itiated ART less than 5 years previously and HIV-negative individuals in Zambia (-0.006, 95% CI -0.00

110 n of N. gonorrhoeae between HIV-positive and HIV-negative individuals receiving pre-exposure prophyla

111 igated 3 rapid urine tests in 372 ambulatory HIV-negative individuals suspected of having TB in South

112 Concerns for nephrotoxicity also extend to HIV-negative individuals using tenofovir disoproxil fuma

113 ive individuals and 78 autopsied brains from HIV-negative individuals were stained for metalloprotein

114 LWH were more likely to harbor oral HPV than HIV-negative individuals, including alpha (39% vs 28%),

115 itiated ART more than 5 years previously and HIV-negative individuals, neither in Zambia (change in m

116 ) and 1.59 (95% CI, .32-8.73) among PLWH and HIV-negative individuals, respectively, and relative exc

117 ociated with diabetes are similar in PWH and HIV-negative individuals, suggesting that diabetes in PW

118 in dolichoectasia appears more prominent in HIV-negative individuals, while apoptosis, mediated by c

119 associated with CD68 staining (P = <.001) in HIV-negative individuals, while caspase 3 was associated

120 NA and CD4+ T-cell counts <500 cells/uL with HIV-negative individuals.

121 ase is poorly described and less expected in HIV-negative individuals.

122 in prevalence rates between HIV-positive and HIV-negative individuals.

123 ance of lipid rafts was higher compared with HIV-negative individuals.

124 dgkin and non-Hodgkin lymphoma compared with HIV-negative individuals.

125 We enrolled the HIV-negative infants of mothers living with HIV who were

126 HIV-negative injectable progestin-only contraceptive use

127 We categorised participants as HIV negative, known HIV infected, or newly diagnosed as

128 study of eGFR among 567 HIV-positive and 117 HIV-negative male participants in the Veterans Aging Coh

129 ransmission from HIV-positive women to their HIV-negative male partners (M-F+) was evaluated.

130 okine-producing Th17 and Tc17 cells in RM of HIV negative men positively correlated with increased mu

131 sets between blood and RM compartments in 62 HIV negative men, focusing primarily on IL-17-producing

132 thereof among human immunodeficiency virus (HIV)-negative men who have sex with men (MSM) over a per

133 viral load) were virally suppressed, and 673 HIV-negative men (40% of 1673) were circumcised in inter

134 d tobacco smoking (1.46 [1.30-1.65]) than in HIV-negative men (both p<0.0001).

135 rs), and compared them with those in 193 763 HIV-negative men and 222 808 HIV-negative women, respect

136 in vitro into AGW and control specimens from HIV-negative men and assessed infection by means of TZM-

137 l-associated invariant T cells in RM from 69 HIV-negative men by flow cytometry.

138 RT with viral suppression; and proportion of HIV-negative men circumcised.

139 288 (37%) of 777 HIV-negative men reported condomless sex with other part

140 523 (72%) of 734 HIV-negative men visited a circumcision facility, with n

141 acco use prevalence between HIV-positive and HIV-negative men was not significant (1.26 [1.00-1.58];

142 A total of 4,685 HIV-negative men who have sex with men (MSM) completed b

143 with women (MSW), 924 HIV-positive MSW, 8213 HIV-negative men who have sex with men (MSM), and 12758

144 Seventy-nine eligible studies included: 1805 HIV-negative men who have sex with women (MSW), 924 HIV-

145 We previously reported on a cohort of HIV-negative men with subclinical endotoxemia linked to

146 etected in 54% of HIV-negative women, 56% of HIV-negative men, and 93% of HIV-positive men and women.

147 as significantly higher in HIV-positive than HIV-negative men, both among MSW (PR = 3.5; 95% CI, 1.6-

148 d was 3.1% in HIV-positive versus 1.1% among HIV-negative men.

149 s who had never been tested or had tested as HIV-negative more than 6 months ago.

150 3686 children born to HIV-negative mothers were assessed at age 18 months (884

151 itive mothers shedding at a higher rate than HIV-negative mothers.

152 d be drawn from findings of children born to HIV-negative mothers; these results are presented in thi

153 sex with other partners was reported by 108 HIV-negative MSM (33%) and 21 heterosexuals (4%).

154 er man per year increased from 1.3 to 1.6 in HIV-negative MSM (Ptrend < .0001) and from 1.6 to 2.3 in

155 In 368 HIV-negative MSM and 72 HIV-negative MSW T-lymphocyte ph

156 + T-cell counts and CD4+/CD8+ ratios between HIV-negative MSM and men who only have sex with women (M

157 Cases in HIV-negative MSM are scarce.

158 re at high risk of acquiring HIV (defined as HIV-negative MSM either reporting one or more casual UAI

159 ribe the epidemic of AHI in HIV-infected and HIV-negative MSM in Lyon, France.

160 secondary syphilis for both HIV-positive and HIV-negative MSM nationally, suggesting interruption of

161 e in PWH, contributes to comorbidity risk in HIV-negative MSM requires further study.

162 ts initial transmission from HIV-infected to HIV-negative MSM through chemsex and traumatic sexual pr

163 From 2010 to 2015, HIV-negative MSM were followed every 6 months.

164 Sexually active and HIV-negative MSM were recruited from communities and ran

165 Of 3259 HIV-negative MSM, 19% were currently using PrEP, 6% had

166 other than HIV may, both in PWH and certain HIV-negative MSM, contribute to a low CD4+/CD8+ ratio.

167 Compared with HIV-negative MSM, HIV-infected individuals had significa

168 Among HIV-negative MSM, the proportion of infections that were

169 This study included 713 HIV-negative MSM, with a median age of 37 years (interqu

170 nce was similar between HIV-positive MSW and HIV-negative MSM.

171 incidence increased in both HIV-infected and HIV-negative MSM.

172 s included HIV-infected MSM; 6 also included HIV-negative MSM.

173 In 368 HIV-negative MSM and 72 HIV-negative MSW T-lymphocyte phenotyping was performed

174 tionship in a group of 250 HIV+ (n = 88) and HIV negative (n = 162) participants from Botswana, aged

175 HIV-negative, non-pregnant Rwandan BV patients were rand

176 12 993 (85%) participants tested HIV negative, of whom 750 (6%) uncircumcised men were ra

177 nfection among human immunodeficiency virus (HIV)-negative or HIV-positive couples followed longitudi

178 Only HIV-negative or HCV-negative participants not on medicat

179 inantly men who have sex with men (MSM)) and HIV-negative otherwise comparable controls, but greater

180 d a similar effect size, in both the PWH and HIV-negative (P <= .05 for all).

181 Blood samples from 15 HIV-negative participants (the uninfected group), 8 HIV-

182 ed among 598 HIV-positive and 550 comparable HIV-negative participants aged >= 45 years of the AGEhIV

183 Eighty-nine HIV-negative participants and 252 HIV-positive participa

184 HIV-negative participants experiencing social (eg, viole

185 normative comparison data on 2400 high-risk HIV-negative participants from 10 voluntary counseling a

186 were adjudicated by 2 physicians for PWH and HIV-negative participants in the Veterans Aging Cohort S

187 57 (45%) of 127 HIV-negative participants were PrEP-aware and only 14 (1

188 take PrEP was low, at 56 (55%) of 102, among HIV-negative participants who were not currently taking

189 Of the 1200 HIV-negative participants, 1085 (90%) were retained at 1

190 % higher mean hsCRP (P = .008) compared with HIV-negative participants, independent of CVD risk facto

191 nd sexual behaviours and HIV incidence among HIV-negative participants.

192 RT and PrEP was initiated by 28 (28%) of 101 HIV-negative participants.

193 infections by comparing newly diagnosed with HIV-negative participants.

194 SD units lower on the OCS-Plus measure than HIV-negative participants.

195 We enrolled 286 PLHIV and 277 HIV-negative participants.

196 exual behaviour questionnaires, HIV testing (HIV-negative partner), and HIV-1 viral load testing (HIV

197 exposure prophylaxis was not reported by the HIV-negative partner, and the HIV-positive partner was v

198 If a seroconversion occurred in the HIV-negative partner, anonymised phylogenetic analysis w

199 isk of within-couple HIV transmission to the HIV-negative partner.

200 r proportion of partners on PrEP among their HIV-negative partners (50.6%, 95% CI: 42.5, 58.8) than b

201 n and not on PrEP) had higher proportions of HIV-negative partners (82.9% (95% CI: 81.1, 84.7) and 90

202 Although 11 HIV-negative partners became HIV-positive (10 MSM; 1 het

203 V status, and 696 [11.6%] of 5997 women with HIV-negative partners).

204 artners, pre-exposure prophylaxis (PrEP) for HIV-negative partners, counselling around timed condomle

205 (33.8) had higher urogenital Cq values than HIV negative patients (32.6) (P<0.03).

206 tumor specimens from 23 HIV-positive and 17 HIV-negative patients (29 men and 11 women; mean [SD] ag

207 HIV-negative patients (aged 18-70 years) with newly diag

208 dal Lymphoma Study Group-32 (IELSG32) trial, HIV-negative patients (aged 18-70 years) with newly diag

209 By use of HIV-negative patients as reference, the aOR of death was

210 primary analysis compared HIV-positive with HIV-negative patients in terms of death during multidrug

211 th LFA and LA appear to be less sensitive in HIV-negative patients than previously described in PLWH.

212 The same analyses were performed in HIV-negative patients with cancer (n = 53), hepatitis C

213 also briefly reviewed all the cases of KS in HIV-negative patients with inflammatory bowel disease.

214 Control samples included HIV-negative patients with lymphomas and HIV-positive pa

215 mples, in a substantial proportion of adult, HIV-negative patients with PTB after a standard 6-month

216 virus (HIV)-negative control individuals, 20 HIV-negative patients with symptomatic Alzheimer disease

217 load at lymphoma diagnosis (53%) than either HIV-negative patients with the same lymphoma type (16%;

218 Of 141 HIV-negative patients, 107 had LA testing and 34 had LFA

219 these patients are the same as those used in HIV-negative patients, cotreatment of tuberculosis with

220 nts presented with HCC at a younger age than HIV-negative patients, this effect appears to be greater

221 n profiles in anal SCCs from HIV-positive vs HIV-negative patients.

222 ent (TME) in anal SCCs from HIV-positive and HIV-negative patients.

223 of IFNG in the TME of both HIV-positive and HIV-negative patients.

224 uated for the diagnosis of cryptococcosis in HIV-negative patients.

225 wing improved sensitivity, including amongst HIV-negative patients.

226 doses are required to match drug exposure in HIV-negative patients.Conclusions: Weight-based dosing o

227 In this study we evaluate urinary LAM in HIV negative, pediatric and adult, pulmonary and extrapu

228 with no significant differences from that of HIV-negative people (change in mean HRQoL score -0.001,

229 ed to compare HRQoL between HIV-positive and HIV-negative people in Zambia and South Africa.

230 T (-0.008, -0.01 to -0.004; p=0.001) than in HIV-negative people, but the magnitudes of difference we

231 roviral therapy (ART) is approaching that of HIV-negative people.

232 Of the 8974 HIV-negative persons (4487 per group), 95% were retested

233 y, 3 separate clinical studies of high-risk, HIV-negative persons conducted in Botswana and Thailand.

234 75,558 HIV-negative persons contributed 166,723 person-years of

235 ive population and an emerging concern among HIV-negative persons receiving pre-exposure prophylaxis.

236 o the costs of ART provision to misdiagnosed HIV-negative persons.

237 lt life expectancy compared with that of the HIV-negative population (ie, the life expectancy deficit

238 In the HIV-negative population, HALE was around 58 years (SD 0.

239 ecificity, but with minimal knowledge in the HIV-negative population.

240 Cryptococcal epidemiology is shifting toward HIV-negative populations who have diverse presentations.

241 We enrolled 96 HIV-negative postmenopausal US women in a phase 2a doubl

242 ure prophylaxis (PrEP) based on tenofovir to HIV-negative pregnant and post-partum women with a subst

243 We analyzed data from 7553 HIV-negative pregnant women enrolled in a multivitamin t

244 Our findings suggest that among HIV-negative pregnant women with high uptake of long-las

245 In this Grand Round, we report eight HIV-negative refugees, who presented with extensively di

246 HIV-negative respondents (both on and not on PrEP) had h

247 placebo-controlled double-blind study of 162 HIV-negative RV144 vaccine recipients, we evaluated 2 ad

248 ed with activation of anti-HIV mechanisms in HIV negative sex workers.

249 Testing of plasma samples that were HIV negative showed no false positive results in the det

250 We studied these factors in 168 HIV-negative South African adolescent females aged 16 to

251 f 6,363 Mycobacterium tuberculosis-infected, HIV-negative South African adolescents aged 12-18 years

252 In a previously published HIV-negative South African case-control study of patient

253 In this prospective cohort, we enrolled HIV-negative South African women aged 18-23 years who we

254 9 specimens of 21 subjects who followed from HIV negative status.

255 nors, VAX004 vaccine recipients, and healthy HIV-negative subjects using a variety of primary and cel

256 Among 601 human immunodeficiency virus (HIV)-negative tested controls, 3% had CRP >/=40 mg/L.

257 reported PrEP awareness more frequently than HIV-negative transgender women who did not.

258 In a new UK cohort of 333 HIV-negative tuberculosis contacts with a median follow-

259 a prospective human immunodeficiency virus (HIV)-negative UK cohort of 333 tuberculosis contacts.

260 HIV-negative uncircumcised men (aged 16-49 years) who co

261 , and viral suppression at 9 months, and for HIV-negative uncircumcised men were visiting a circumcis

262 of prevalent pulmonary tuberculosis (TB) in HIV negative/unknown individuals was developed to assist

263 d HIV-negative women; between 2012 and 2014, HIV-negative VTS children (332 HIV exposed, 574 HIV unex

264 ent partnerships where both individuals were HIV-negative, we compared observed concordance in preexp

265 Sexually active women who were HIV negative were randomly assigned (3:1) to a tenofovir

266 linical screening, 93% of the women who were HIV-negative were confirmed as clinically eligible for P

267 A total of 17,870 persons who were initially HIV-negative were followed for 94,427 person-years; amon

268 ples from 14 donors (13 HIV-infected and one HIV-negative) who yielded data meeting quality threshold

269 portion of all adults (both HIV positive and HIV negative) with a detectable viral load (local preval

270 rent or guardian, and individuals who tested HIV-negative within the past 3 months but who reported a

271 atively associated with motor function among HIV-negative women (b = -3.57, SE = 1.08, P <= 0.001).

272 ed with cervical cytohistopathology, both in HIV-negative women (from 1% [5/498] in normal cytology u

273 ociated with cervical high-risk HPV, both in HIV-negative women (from 2% [11/527] in cervical high-ri

274 ory pathways during pregnancy in a cohort of HIV-negative women (n = 1,628), with a median age of 21

275 ence of 44% [101/228] for cervical cancer in HIV-negative women (PR vs normal cytology 14.1, 11.1-17.

276 Eligible participants were HIV-negative women aged 16 years or older with a viable

277 In this cohort study, HIV-negative women aged 18-39 years were recruited at tw

278 r 100 person-years (95% CI 49.8-125.4) among HIV-negative women and 36.7 per 100 person-years (29.1-4

279 5-85%, led to specificities of 91.3-95.3% in HIV-negative women and 77.0-85.8% in HIV-positive women.

280 ghest in women who had started ART, lower in HIV-negative women and lowest in ART-naive HIV-positive

281 ssociated with persistent hrHPV infection in HIV-negative women but not in HIV-positive women.

282 ion of malaria infection during pregnancy in HIV-negative women currently relies on the use of long-l

283 ated with anal precancer in HIV+ and at-risk HIV-negative women from the Atlanta Women's Interagency

284 At baseline, HIV+ women compared with HIV-negative women had a higher mean +/- SD food-insecur

285 raepithelial neoplasia grade 2 or greater in HIV-negative women using manufacturer-defined cycle thre

286 anal cancer prevention in high-risk groups, HIV-negative women with cervical HPV16, especially those

287 -positive women older than 45 years (5/20 in HIV-negative women, 12/52 in HIV-positive women).

288 llment, HPV infection was detected in 54% of HIV-negative women, 56% of HIV-negative men, and 93% of

289 In HIV-negative women, anal HPV16 prevalence was 41% (447/1

290 ghest in women who had started ART, lower in HIV-negative women, and lowest in ART-naive HIV-positive

291 hose in 193 763 HIV-negative men and 222 808 HIV-negative women, respectively.

292 In HIV-negative women, women with Lactobacillus dominant mi

293 also higher in women on ART when compared to HIV-negative women.

294 acco use (1.32 [1.03-1.69]; p=0.030) than in HIV-negative women.

295 confidence interval, 1.59-1.67) and those in HIV-negative women.

296 infected women with delivery at term or with HIV-negative women.

297 or anal cancer screening in HIV+ and at-risk HIV-negative women.

298 tudy (VTS) supported EBF in HIV-positive and HIV-negative women; between 2012 and 2014, HIV-negative

299 all participants in a prospective cohort of HIV-negative YBMSM aged 18-29.

300 undiagnosed HIV-positive youths, and linking HIV-negative youths to relevant prevention services.